Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients
Status:
Not yet recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
MORE-T trial is designed to investigate the effect of Tamoxifen 40mg (vs. Tamoxifen 20mg) for
2wks in presurgical setting.
The greater reduction in Ki-67 might be observed in Tamoxifen 40mg arm compared to the
Tamoxifen 20mg arm.
Open Label, Phase 2, Randomized with 1:1 allocation